Felbatol - Patient Consent Form Espanol

Click here to download the Felbatol® Patient Consent Form.

The materials above require the Adobe® Acrobat® Reader®. You can download the reader for free by clicking here.

Indications & Usage
Indications

FELBATOL (felbamate) should not be used as initial therapy in epilepsy (see Warnings in full Prescribing Information)
FELBATOL is recommended for use only in those patients who do not respond well to other treatments and whose epilepsy is so severe that the potential risk of developing aplastic anemia (a severe blood disorder) or liver failure is outweighed by the potential benefit of felbamate treatment.
After the patient or their caregiver has discussed the potential risks of Felbatol treatment with their doctor and have provided written consent, FELBATOL treatment can be considered. FELBATOL, by itself or in combination with other drugs is approved for the treatment of partial seizures, with or without generalization, in adults with epilepsy, and as combination therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children.

Additional Safety Information

FELBATOL should not be used in patients with a history of any blood or liver problems
Routine blood tests should be performed that can help identify potential blood or liver problems.
FELBATOL should be discontinued if there is evidence that blood or liver problems have occurred Adverse Events
The most common adverse experiences observed in clinical studies are loss of appetite, vomiting, insomnia, nausea, headache, and sleepiness